Johnson & Johnson (JNJ) Position Raised by Cwm LLC

Cwm LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.3% in the second quarter, HoldingsChannel reports. The firm owned 16,569 shares of the company’s stock after purchasing an additional 682 shares during the period. Cwm LLC’s holdings in Johnson & Johnson were worth $2,011,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Financial Gravity Wealth Inc. acquired a new stake in shares of Johnson & Johnson during the 1st quarter worth approximately $105,000. WP Advisors LLC acquired a new stake in shares of Johnson & Johnson during the 2nd quarter worth approximately $108,000. FNY Investment Advisers LLC acquired a new stake in shares of Johnson & Johnson during the 2nd quarter worth approximately $117,000. Live Your Vision LLC grew its position in shares of Johnson & Johnson by 58.3% during the 2nd quarter. Live Your Vision LLC now owns 1,363 shares of the company’s stock worth $172,000 after buying an additional 502 shares during the period. Finally, Signition LP acquired a new stake in shares of Johnson & Johnson during the 1st quarter worth approximately $204,000. Hedge funds and other institutional investors own 66.60% of the company’s stock.

Johnson & Johnson stock opened at $145.34 on Friday. Johnson & Johnson has a fifty-two week low of $118.62 and a fifty-two week high of $148.32. The company has a market cap of $382.50 billion, a P/E ratio of 19.91, a PEG ratio of 2.23 and a beta of 0.58. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.72.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 16th. The company reported $2.05 earnings per share for the quarter, topping the consensus estimate of $2.03 by $0.02. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. The business had revenue of $20.35 billion for the quarter, compared to analyst estimates of $20.05 billion. During the same quarter last year, the firm earned $1.90 EPS. Johnson & Johnson’s quarterly revenue was up 3.6% compared to the same quarter last year. Analysts expect that Johnson & Johnson will post 8.16 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 11th. Investors of record on Tuesday, November 27th will be paid a dividend of $0.90 per share. This represents a $3.60 annualized dividend and a yield of 2.48%. The ex-dividend date of this dividend is Monday, November 26th. Johnson & Johnson’s payout ratio is 49.32%.

In other Johnson & Johnson news, insider Joaquin Duato sold 40,000 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, November 7th. The shares were sold at an average price of $144.36, for a total value of $5,774,400.00. Following the transaction, the insider now owns 112,848 shares of the company’s stock, valued at $16,290,737.28. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Ronald A. Kapusta sold 7,899 shares of Johnson & Johnson stock in a transaction that occurred on Friday, September 7th. The shares were sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the completion of the transaction, the chief accounting officer now directly owns 25,725 shares in the company, valued at approximately $3,528,955.50. The disclosure for this sale can be found here. Insiders have sold a total of 85,340 shares of company stock worth $11,992,396 in the last three months. 0.22% of the stock is owned by insiders.

Several equities research analysts have recently commented on JNJ shares. Credit Suisse Group lifted their price target on shares of Johnson & Johnson from $149.00 to $152.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 17th. Citigroup lifted their price target on shares of Johnson & Johnson from $137.00 to $148.00 and gave the stock a “neutral” rating in a research report on Monday, October 22nd. Wells Fargo & Co reiterated an “outperform” rating and set a $160.00 price target on shares of Johnson & Johnson in a research report on Friday, September 14th. Raymond James lifted their price target on shares of Johnson & Johnson from $144.00 to $149.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 17th. Finally, ValuEngine upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Saturday, July 28th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the stock. Johnson & Johnson currently has an average rating of “Hold” and a consensus target price of $142.54.

ILLEGAL ACTIVITY NOTICE: “Johnson & Johnson (JNJ) Position Raised by Cwm LLC” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/11/10/johnson-johnson-jnj-position-raised-by-cwm-llc.html.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: What are earnings reports?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply